Panacea Biotec’s Subsidiary Launches Premium Baby Diapers and Wipes

Panacea Biotec is a worldwide manufacturer of generic and speciality pharmaceuticals and vaccines, with main offices situated in New Delhi, Mumbai, and Lalru. The company is involved in the research, development, production, and marketing of pharmaceutical formulations, vaccines, biosimilars, and natural products.

Launches New Diaper Brand NikoMom

On January 3, 2025, shares of Panacea Biotec Ltd. surged by over 5% after the company announced  on January 2, 2025, the introduction of its new diaper brand, ‘NikoMom.’ This brand will encompass the company’s range of diapers and wipes. 

Currently, the brand will focus on the domestic market, although the company indicated that it plans to roll out baby care products in select international markets in the future.

Panacea Biotec Q2 FY25 Results

In its financial results for Q2 FY25, Panacea Biotec reported a notable enhancement in performance. The company’s total income climbed by 27.33% compared to the previous year, reaching ₹147.35 crore, thanks to robust growth in its primary business sectors. It recorded an operating profit of ₹1.09 crore, indicating a recovery from an operating loss in the same quarter last year, which signifies improved cost efficiency and operational performance.

The Profit After Tax (PAT) experienced a commendable improvement, achieving ₹4.80 crore, in contrast to a net loss recorded in the same quarter of the previous year. Additionally, the operating margin saw an increase of 0.74%, reflecting enhanced profitability from core operations. These results underscore the company’s capability to strengthen its financial position and seize growth opportunities within the healthcare sector.

Share Price Performance 

Panacea Biotec’s share price was trading at ₹441.60 on the NSE at 11:35 AM on January 6, 2025. In the last year, the company’s shares have risen by over 130%.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.